Financings
Celsion Corp. raised $13 million in a registered direct offering and $5.4 million in a private placement.
Coronado Biosciences Inc. filed a Form-10 with the SEC as a non-IPO route to public listing.
gIcare Pharma Inc. raised $7 million in Series A financing to develop a colonic analgesic.
NeoStem Inc. is raising about $16.5 million in a public offering of stock and warrants.
Protox Therapeutics Inc. entered a $15 million loan agreement with Oxford Finance LLC.
SARcode Bioscience Inc. raised $44 million in a Series B financing.
Ventrus Biosciences Inc. raised $45 million in a public stock offering.
Deals
Allergan Inc. acquired dermatology company Vicept Therapeutics Inc. for $275 million.
AMAG Pharmaceuticals Inc. and Allos Therapeutics Inc. are merging in a $686 million all-stock deal.
BioSante Pharmaceuticals Inc. licensed a melanoma vaccine to the John P. Hussman Foundation.
Icagen Inc. is being acquired by partner Pfizer Inc. for $56 million.
NeoStem Inc. acquired privately held stem cell firm Amorcyte Inc. for $18 million.
Vical Inc. signed a potential $130 million deal with Astellas Pharma Inc. for TransVax in transplant.
. . . And More
AstraZeneca plc's Brilinta (ticagrelor) gained FDA approval for acute coronary syndromes.
AstraZeneca plc and Bristol-Myers Squibb Co.'s diabetes drug dapagliflozin got rejected by an FDA advisory panel.
Dynavax Technologies Corp.'s hepatitis B vaccine Heplisav met its Phase III endpoints, but had a manufacturing inconsistency.
Exelixis Inc. said partner Bristol-Myers Squibb Co. handed back rights to XL281 .
Nabi Biopharmaceuticals Inc.'s smoking cessation vaccine NicVAX failed Phase III.
Transcept Pharmaceuticals Inc. is eliminating 45 percent of its work force.